Neosomatas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 46,498 | 29,186 | 20,248 | 29,888 | 27,242 | 26,255 | 21,386 | 23,105 |
| Profit before tax | 1,045 | 1,681 | -11,304 | -6,248 | 2,026 | 221 | 2,950 | -3,795 |
| Net profit | 993 | 1,597 | -11,304 | -6,248 | 1,925 | 210 | 2,773 | -3,795 |
| Equity | 65,938 | 67,535 | 26,231 | 19,983 | 21,908 | 22,118 | 24,891 | 21,096 |
| Liabilities | 17,216 | 16,483 | 9,236 | 6,084 | 2,487 | 685 | 2,621 | 1,484 |
| Non-current assets | 22,701 | 19,077 | 15,180 | 13,041 | 10,970 | 8,944 | 6,919 | 4,895 |
| Current assets | 60,453 | 64,941 | 20,287 | 13,026 | 13,425 | 13,859 | 20,593 | 17,685 |
| Total assets | 83,154 | 84,018 | 35,467 | 26,067 | 24,395 | 22,803 | 27,512 | 22,580 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 3,095 | 3,029 | 1,446 |
| Social insurance contributions | - | - | - | - | - | 1,167 | - | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | -3.7% | -37.2% | -30.6% | +47.6% | -8.9% | -3.6% | -18.5% | +8.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.2% | 1.9% | -31.9% | -24.0% | 7.9% | 0.9% | 10.1% | -16.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 1.5% | 2.4% | -43.1% | -31.3% | 8.8% | 0.9% | 11.1% | -18.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.1% | 5.5% | -55.8% | -20.9% | 7.1% | 0.8% | 13.0% | -16.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 2.2% | 5.8% | -55.8% | -20.9% | 7.4% | 0.8% | 13.8% | -16.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.2 | 0.4 | 0.3 | 0.1 | 0.0 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 11,625 | 7,297 | 5,062 | 7,472 | 6,811 | 6,807 | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Neosomatas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-01-09 | 2024-01-31 | 175.89 |
| 2024-01-03 | 2024-01-08 | 226.70 |
| 2023-12-19 | 2024-01-02 | 168.07 |
| 2023-12-01 | 2023-12-18 | 117.26 |
| 2023-11-03 | 2023-11-30 | 58.63 |
| 2022-10-18 | 2022-10-19 | 0.01 |
| 2022-07-18 | 2022-08-01 | 438.57 |
Neosomatas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-07-01 | 2026-07-07 | 0.04 |
| 2024-11-01 | 2024-11-25 | 0.4 |
| 2024-10-01 | 2024-10-16 | 0.04 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Neosomatas, MB (code 300014921) is a Small partnership engaged in the manufacture of prepared feeds for farm animals. In 2025, the company generated revenue of €23.1K, up 8.0% year on year, after €21.4K in 2024 and €26.3K in 2023, showing a decline from 2023 followed by a partial recovery. Profitability weakened materially in 2025, with net loss of €3.8K and a profit margin of -16.4%, compared with net profit of €2.8K and a 13.0% margin in 2024, and €210 in profit in 2023. Balance sheet size remained modest, with total assets of €22.6K at the end of 2025, down from €27.5K in 2024. Equity stood at €21.1K and liabilities at €1.5K, leaving a very strong equity ratio of 93.4% and a low debt-to-equity level of 0.07. Return metrics were negative in 2025, with ROE at -18.0% and ROA at -16.8%. Asset turnover was 1.02x, indicating revenue close to the asset base.